3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Lymphoma
5
Central Nervous System Neoplasms
4
Neuroblastoma
2
Meningeal Carcinomatosis
2
Brain Neoplasms
2
Vasculitis, Central Nervous System
1
Thrombocytopenia
1
Stiff-Person Syndrome
1
Rhabdoid Tumor
1
Recurrence
1
Rasmussen subacute encephalitis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
1
Opsoclonus-Myoclonus Syndrome
1
Neurotoxicity Syndromes
1
Neuromyelitis Optica
1
Neurofibromatosis 1
1
Myasthenia Gravis
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Lambert-Eaton Myasthenic Syndrome
1
Intraocular Lymphoma
1
HIV Infections
1
Ependymoma
1
Drug-Related Side Effects and Adverse Reactions
1
Breast Neoplasms
1
Autoimmune Diseases of the Nervous System
1
Interventions
Temozolomide
26
Magnetic Resonance Spectroscopy
19
Etoposide
12
Cyclophosphamide
12
Radiotherapy
11
Bevacizumab
10
Filgrastim
9
Biopsy
8
Carboplatin
7
X-Rays
6
Thiotepa
6
Specimen Handling
6
Phantoms, Imaging
6
Cisplatin
6
Carmustine
6
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Irinotecan
5
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
5
sargramostim
4
Radiation
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
olaparib
3
etoposide phosphate
3
Vincristine
3
Surveys and Questionnaires
3
Lapatinib
3
Gadolinium DTPA
3
Azacitidine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Ependymoma
×
Cytarabine
×
CNS
×
Clear all
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled